cell therapy

bluebird bio Inc Shares Up After Phase 1 clinical Study Update

bluebird bio Inc Shares Up After Phase 1 clinical Study Update

Shares of the innovative clinical-stage biotechnology company bluebird bio Inc. (NASDAQ: BLUE) have jumped more than 13% Tuesday, after the company together with their partner Celgene Corporation (NASDAQ: CELG) reported updated results from the ongo..